II. Preparations
- Tenofovir Disoproxil Fumarate (TDF)
- Original Tenofovir formulation and used in Stribild, Truvada and Complera
- Tenofovir Alafenamide Fumarate (TAF)
- Tenofovir formulation released in 2016 and used in Genvoya, Descovy, Odefsey
- TAF appears to have less adverse Renal Function and Bone Mineral Density effects than the original TDF
III. Mechanism
IV. Adverse Effects
- See nRTI for adverse effects attributed to the class
- Renal dysfunction
- Increased Serum Creatinine
- Proteinuria
- Electrolyte abnormalities
- Acute Renal Failure (1% risk)
- Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
- Gastrointestinal
- Miscellaneous
- Headache
- Hepatitis B flares on withdrawal of medication
V. Dosing
- Dose: 300 mg orally daily
VI. References
Images: Related links to external sites (from Bing)
Related Studies (from Trip Database) Open in New Window
| viread (on 3/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| VIREAD 300 MG TABLET | $34.28 each | |
Ontology: Tenefovir (C2735014)
| Concepts | Organic Chemical (T109) , Antibiotic (T195) |
| LNC | MTHU034726 |
| English | Tenefovir |
